MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19

被引:4
作者
Gong, Yanping [1 ]
Wu, Wenshuang [1 ]
Zou, Xiuhe [1 ]
Liu, Feng [1 ]
Wei, Tao [1 ]
Zhu, Jingqiang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Thyroid & Parathyroid Surg Ctr, Chengdu 610041, Sichuan, Peoples R China
关键词
ARPP19; cell proliferation; miR-26a; tamoxifen; thyroid cancer; IN-VITRO; EXPRESSION; CARCINOMAS; MICRORNA; GROWTH; APOPTOSIS; MIGRATION; THERAPY; ARPP-19; REGIONS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
miRNA, which involves in pathogenesis of thyroid cancer via different targets, has been found aberrantly expressed in thyroid cancer. Modes of actions of miR-26a in papillary thyroid carcinoma (PTC), however, have not been fully understood to this date. In vitro results obtained from this research confirmed miR-26a was down-regulated in PTC cells (i.e. TPC-1 and BCPAP) where the down-regulation of miR-26a was found to be able to promote cell proliferation. In order to explore the mechanisms, potential targets of miR-26a were postulated: cAMP regulated phosphoprotein 19 (ARPP19) turned out to be the target of miR-26a and it was by depleting ARPP19 was the cell proliferation be suppressed. This suggested that miR-26a regulated cell proliferation by targeting ARPP19. In addition, such a depletion of ARPP19 sensitized PTC cells to tamoxifen (TMX) treatment. The above findings indicated miR-26a was a target of interest regarding the treatment of refractory thyroid carcinomas.
引用
收藏
页码:1030 / 1039
页数:10
相关论文
共 50 条
[31]   RETRACTED: MiR-524 inhibits cell proliferation and induces cell apoptosis in thyroid cancer via targeting SPAG9 (Retracted Article) [J].
Zhen, Z. ;
Dong, F. ;
Shen, H. ;
Wang, Q. -G. ;
Yang, L. ;
Hu, J. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2018, 22 (12) :3812-3818
[32]   miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma [J].
Ye, Xiaojuan ;
Chen, Xiaofang .
ONCOLOGY LETTERS, 2019, 17 (01) :372-378
[33]   MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells [J].
Erdmann, Kati ;
Kaulke, Knut ;
Rieger, Christiane ;
Salomo, Karsten ;
Wirth, Manfred P. ;
Fuessel, Susanne .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (11) :2249-2261
[34]   MiR-26a promotes apoptosis of porcine granulosa cells by targeting the 3β-hydroxysteroid-Δ24-reductase gene [J].
Zhang, Xiaodong ;
Tao, Qiangqiang ;
Shang, Jinnan ;
Xu, Yiliang ;
Zhang, Liang ;
Ma, Yingchun ;
Zhu, Weihua ;
Yang, Min ;
Ding, Yueyun ;
Yin, Zongjun .
ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES, 2020, 33 (04) :547-555
[35]   MiR-1256 inhibits cell proliferation and cell cycle progression in papillary thyroid cancer by targeting 5-hydroxy tryptamine receptor 3A [J].
Wu, Chaowen ;
Ma, Liyuan ;
Wei, Hongfa ;
Nie, Furong ;
Ning, Jie ;
Jiang, Tao .
HUMAN CELL, 2020, 33 (03) :630-640
[36]   MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1 [J].
Chang, Lei ;
Zhang, Dongya ;
Shi, Huirong ;
Bian, Yangyang ;
Guo, Ruixia .
ONCOTARGET, 2017, 8 (48) :84384-84395
[37]   Mir-483 inhibits colon cancer cell proliferation and migration by targeting TRAF1 [J].
Niu, Zi-Yu ;
Li, Wen-Li ;
Jiang, Da-Lei ;
Li, Yan-Song ;
Xie, Xiang-Jun .
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (09) :479-486
[38]   miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2 [J].
Jiang, Pan ;
Mao, Lianghao ;
Lei, Xuan ;
Luo, Chunshan ;
Zhang, Yiming ;
Zhong, Xinyu ;
Yin, Zhenyu ;
Xu, Xiaofeng ;
Li, Dapeng ;
Zheng, Qiping .
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07) :3464-+
[39]   MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1 [J].
Wei, Zhenxing ;
Chang, Kunpeng ;
Fan, Chongsheng ;
Zhang, Yang .
CANCER CELL INTERNATIONAL, 2020, 20 (01)
[40]   MIR-376-5P INHIBITS PROSTATE CANCER CELL PROLIFERATION AND INDUCES APOPTOSIS BY TARGETING TCTN1 [J].
Cheng, Huan ;
Chen, Yue ;
Xue, Song ;
Wen, Rumin ;
Chen, Jiacun ;
Wang, Junqi .
ACTA MEDICA MEDITERRANEA, 2021, 37 (04) :2169-2175